Key Highlights

  • TransCode Therapeutics shares settled down about 6%, near $2.05, versus Friday's $2.18.
  • The company published preclinical data on TTX-MC138 in a mouse model of breast-cancer bone metastasis.
  • The candidate reduced miR-10b, raised tumor-suppressor HOXD10, and improved survival with no systemic toxicity in the model.
  • The publication does not represent new human clinical data.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares settled down about 6%, near $2.05, versus Friday's $2.18, after the company published preclinical data in the Journal Cancers on TTX-MC138 in a mouse model of breast-cancer bone metastasis.

What Happened

After systemic dosing, the candidate accumulated in bone lesions, cut expression of miR-10b, a metastasis-linked microRNA, raised the tumor-suppressor HOXD10, improved survival, and showed no systemic toxicity in the model. The article went online August 23, with the company publicizing it today.

Market Reaction

Shares fell as the market treated the publication as supportive preclinical biology rather than a new clinical catalyst; TransCode has already completed Phase 1a in metastatic cancer and started a Phase 2a trial in ctDNA-positive colorectal cancer, and the bone-metastasis mouse data does not change that clinical timeline.

Outlook

Continued progress in TransCode's ongoing Phase 2a colorectal cancer trial represents the next disclosed clinical milestone likely to matter more to the stock than additional preclinical publications.